In vitro antimicrobial activity of a new quinolone, levofloxacin, against atypical mycobacteria
Abstract
We measured th in vitro antimicrobial activity of a new quinolone, levofloxacin (LVFX) against seven clinically isolated species of atypical mycobacteria, including 30 strains of M. avium complex. 8 of M. fortuitum, 4 of M. scrofulaceum, 2 of M. kansasii, 2 of M. gordonae, and 1 of M. chelonae (subsp chelonae). LVFX showed a potent antimicrobial activity against M. kansasii, M. gordonae and M. chelonae (subsp chelonae). In addition, it was suggested that LVFX may be effective for the treatment of infections caused by M. avium complex, since satisfactory antimicrobial activity was displayed against some strains of M. avium complex. Considering the fact that LVFX shows good concentration levers in sputum, this drug could be used in the chemotherapy against the infection with M. avium complex.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.